Molecular and biochemical features in Alzheimer's disease

Current Pharmaceutical Design

Volumn 12, Issue 33, 2006, Pages 4389-4408

  Pallàs, Mercè ^a   Camins, Antoni ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

amyloid; Acetylcholine; Apoptosis; Cyclin dependent kinases; Glutamate receptors; Neuronal cell death; Presenilins; Secretases

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; [1 [(1 FORMYL 2 PHENYLETHYL)CARBAMOYL] 2 METHYLPROPYL]CARBAMIC ACID BENZYL ESTER; ACETYLCHOLINE; ALPHA SECRETASE; ALPHA TOCOPHEROL; AMYLOID; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ASCORBIC ACID; CALPASTATIN; CARNITINE; CELECOXIB; CEP 1347; CHOLINESTERASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR; FLAVOPIRIDOL; LITHIUM; MELATONIN; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; NOTCH RECEPTOR; PLACEBO; PRESENILIN 1; PRESENILIN 2; ROFECOXIB; ROSCOVITINE; TAU PROTEIN; UBIDECARENONE; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; CALCIUM BALANCE; CHOLINERGIC NERVE CELL; CLINICAL FEATURE; CLINICAL TRIAL; DRUG RESEARCH; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; FENTON REACTION; GENE MUTATION; HIPPOCAMPUS; HUMAN; MITOCHONDRION; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; SENILE PLAQUE; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; HUMANS;

EID: 33750885775     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206778792967     Document Type: Review

References (252)

1. Selkoe DJ. Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat Cell Biol 2004; 6: 1054-61.
2. Selkoe DJ. Alzheimer disease: mechanistic understanding predicts novel therapies. Ann Intern Med 2004; 140: 627-38.
3. Dickson DW. Apoptotic mechanism in Alzheimer neurofibrillary degeneration: cause or effect. J Clin Invest 2004; 114: 23-7.
4. Talamo BR, Feng WH, Perez-Cruet M, Adelman L, Kosik K, Lee MY, et al. Pathologic changes in olfactory neurons in Alzheimer's disease. Ann N Y Acad Sci 1991; 640: 1-7.
5. Lu Q, Wood JG. Functional studies of Alzheimer's disease tau protein. J Neurosci 1993; 13: 508-15.
6. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984; 120: 885-90.
7. Citron M, Diehl TS, Gordon G, Biere AL, Seubert P, Selkoe DJ. Evidence that the 42- and 40- amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities. Proc Natl Acad Sci USA 1996; 93: 13170-5.
8. Rottkamp CA, Atwood CS, Joseph JA, Nunomura A, Perry G, Smith MA. The state versus amyloid-β: the trial of the most wanted criminal in Alzheimer disease. Peptides 2002; 23: 1333-41.
9. Vassar R. BACE1: the beta-secretase enzyme in Alzheimer's disease. J Mol Neurosci 2004; 23: 105-14.
10. Bertram L, Tanzi RE. The current status of Alzheimer's disease genetics: what do we tell the patients? Pharmacol Res 2004; 50: 385-96.
11. Esler WP, Kimberly WT, Ostaszewski BL, Diehl TS, Moore CL, Tsai JY, et al. Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1. Nat Cell Biol 2000; 2: 428-34.
12. Chan SL, Culmsee C, Haughey N, Klapper W, Mattson MP. Presenilin-1 mutations sensitize neurons to DNA damage-induced death by a mechanism involving perturbed calcium homeostasis and activation of calpains and caspase-12. Neurobiol Dis 2002; 11: 2-19.
13. Chan SL, Furukawa K, Mattson MP. Presenilins and APP in neuritic and synaptic plasticity implications for the pathogenesis of Alzheimer's disease. NeuroMol Med 2002; 2: 166-96.
14. Wilson CA, Doms RW, Lee VMY. Distinct presenilin-dependent and presenilin-independent gamma-secretases are responsible for total cellular Aβ production. J Neurosci Res 2003; 74: 361-9.
15. Small DH, McLean CA. Alzheimer's disease and the amyloid β protein: what is the role of amyloid? J Neurochem 1999; 73: 443-9.
16. Nunan J, Small DH. Regulations of APP by alfa, beta and gamma-secretases. FEBS Lett 2000; 483: 6-10.
17. Walter J, Kaether C, Steiner H, Haass C. The cell biology of Alzheimer's disease: uncovering the secrets of secretases. Curr Opin Neurol 2001; 11: 585-90.
18. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996; 2: 864-70.
19. Younkin SG. The role of Ab 42 in Alzheimer's disease. J Physiol 1998; 92: 289-92.
20. Vassar R, Bennet BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, et al. β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999; 286: 735-41.
21. Zhu GF, Wang D, Lin YH, McMahon T, Koo EH, Messing RO. Protein kinase C epsilon suppresses Ab production and promotes activation of alpha-secretase. Biochem Biophys Res Commun 2001; 285: 997-1006.
22. Esch FS, Keim PS, Beattie EC. Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science 1990; 248: 1122-4.
23. Wolfe MS. Secretase targets for Alzheimer's disease: identification and therapeutic potential. J Med Chem 2001; 44: 2039-60.
24. Haass C, Hung AY, Selkoe DJ, Teplow DB. Mutations associated with a locus for familial Alzheimer's disease result in alternative processing of amyloid beta-protein precursor. J Biol Chem 1994; 269: 17741-8.
25. De Jonghe C, Zehr C, Yager D, Prada CM, Younkin S, Hendriks L, et al. Flemish and Dutch mutations in amyloid beta precursor protein have different effects on amyloid beta secretion. Neurobiol Dis 1998; 5: 281-6.
26. Watson DJ, Selkoe DJ, Teplow DB. Effects of the amyloid precursor protein Glu693→Gln 'Dutch' mutation on the production and stability of amyloid beta-protein. Biochem J 1999; 340: 703-9.
27. Mattson MP, Cheng B, Culwell AR, Esch FS, Lieberburg I, Rydel RE. Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron 1993; 10: 243-54.
28. Small DH. The role of the amyloid precursor protein (APP) in Alzheimer's disease: does the normal function of APP explain the topography of neurodegeneration? Neurochem Res 1998; 23: 795-806.
29. Mok SS, Clippingdale AB, Beyreuther K, Masters CL, Barrow CJ, Small DH. Aβ peptides and calcium influence secretion of the amyloid protein precursor from chick sympathetic neurons in culture. J Neuros Res 2000; 61: 449-57.
30. Landman N, Kim TW. Got RIP? Presenilin-dependent intramembrane proteolysis in growth factor receptor signalling. Cytokin Growth Factor Rev 2004; 15: 337-51.
31. Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M, et al. Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc Nat Acad Sci USA 1999; 96: 3922-7.
32. Buxbaum JD, Liu KN, Luo Y, Slack JL, Stocking KL, Peschon JJ, et al. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem 1998; 273: 27765-7.
33. Sabo SL, Lanier LM, Ikin AF, Khorkova O, Sahasrabudhe S, Greengard P, et al. Regulation of beta-amyloid secretion by FE65, an amyloid protein precursor-binding protein. J Biol Chem 1999; 274: 7952-7.
34. Schlöndorff J, Becherer JD, Blobel CP. Intracellular maturation of the tumor necrosis factor a convertase(TACE). Biochem J 2000; 347: 131-8.
35. Esler WP, Stimson ER, Jennings JM, Vinters HV, Ghilardi JR, Lee JP, et al. Alzheimer's disease amyloid propagation by a template-dependent dock-lock mechanism. Biochemistry 2000; 39: 6288-95.
36. Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL, et al. Amyloid beta-peptide produced by cultured cells during normal metabolism. Nature 1992; 359: 322-5.
37. Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, et al. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nature Neurosci 2001; 4: 231-2.
38. Cai H, Wang Y, McCarthy D Wen H, Borchelt DR, Price DL, et al. BACE1 is the major beta-secretase for generation of Ab peptides by neurons. Nature Neurosci 2001; 4: 233-4.
39. Seubert P, Oltersdorf T, Lee MG, Barbour R, Blomquist C, Davis DL, et al. Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide. Nature 1993; 361: 260-3.
40. Li Y-M. γ-Secretase: a catalyst of Alzheimer disease and signal transduction. Mol Intervent 2001; 1: 198-207.
41. Sisodia SS. An accomplice for γ-secretase brought into focus. Science 2000; 289: 2296-7.
42. Selkoe DJ. Presenilin, notch, and the genesis and treatment of Alzheimer's disease. Proc Natl Acad Sci USA 2001; 98: 11039-41.
43. Jarrett JT, Berger EP, Lansbury PT Jr. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993; 32: 4693-7.
44. Zhang Y, McLaughlin R, Googyer C, LeBlanc A. Selective cytotoxicity of intracellular amyloid β peptide 1-42 through p53 and Bax in cultured primary neurons, J Cell Biol 2002; 156: 519-29.
45. Wolfe MS, Citron M, Diehl TS, Xia W, Donkor IO, Selkoe DJ. A substrate-based difluoro ketone selectivity inhibits Alzheimer's c-secretase activity. J Med Chem 1998; 41: 6-9.
46. Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, et al. Increased amyloid-beta 42 (43) in brains of mice expressing mutant presenilin 1. Nature 1996; 383: 710-3.
47. Sisodia SS, Kim SH, Thinakaran G. Function and dysfunction of the presenilins. Am J Hum Genet 1999; 65: 7-12.
48. Kostyszyn B, Cowburn RF, Seiger A, Kjaeldgaard A, Sundstrom E. Expression of presenilin-1 and Notch-1 receptor in human embryonic CNS. Neuroscience 2001; 103: 885-98.
49. Cook DG, Sung JC, Golde TE, Felsenstein KM, Wojczyk BS, Tanzi RE, et al. Expression and analysis of presenilin 1 in a human neuronal system:localization in cell bodies and dendrites. Proc Natl Acad Sci USA 1996; 93: 9223-8.
50. Ribaut-Barassin C, Moussaoui S, Brugg B, Haeberle AM, Huber G, Imperato A, et al. Hemisynaptic distribution patterns of presenilins and beta-APP isoforms in the rodent cerebellum and hippocampus. Synapse 2000; 35: 96-110.
51. Selkoe DJ. Presenilin, Notch, and the genesis and treatment of Alzheimer's disease. Proc Natl Acad Sci USA 2001; 98: 1039-41.
52. Mattson MP, Chan SL. Dysregulation of cellular calcium homeostasis in Alzheimer's disease: bad genes and bad habits. J Mol Neurosci 2001; 17: 205-24.
53. Shepherd CE, Gregory GC, Vickers JC, Halliday GM. Novel 'inflammatory plaque' pathology in presenilin-1 Alzheimer's disease. Neuropathol Appl Neurobiol 2005; 31: 503-11.
54. Mattson MP, Chan SL, Camandola S. Presenilin mutations and calcium signaling defects in the nervous and immune systems. Bioessays 2001; 23: 733-44.
55. Guo ZH, Mattson MP. In vivo 2-deoxyglucose administration preserves glucose and glutamate transport and mitochondrial function in cortical synaptic terminals after exposure to amyloid beta-peptide and iron: evidence for a stress response. Exp Neurol 2000; 166: 173-9.
56. Guo Q, Fu W, Holtsberg FW, Steiner SM, Mattson MP. Superoxide mediates the cell-death-enhancing action of presenilin-1 mutations. J Neurosci Res 1999; 56: 457-70.
57. Lemere CA, Lopera F, Kosik KS, Lendon CL, Ossa J, Saido TC, et al. The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology. Nat Med 1996; 2: 1146-50.
58. Donoviel DB, Hadjantonakis AK, Ikeda M, Zheng H, Hyslop PS, Bernstein A. Mice lacking both presenilin genes exhibit early embryonic patterning defects. Genes Develop 1999; 13: 2801-10.
59. Herreman A, Hartmann D, Annaert W, Saftig P, Craessaerts K, Serneels L, et al. Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. Proc Natl Acad Sci USA 1999; 96: 11872-7.
60. Tomita T, Maruyama K, Saido TC, Kume H, Shinozaki K, Tokuhiro S, et al. The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid beta protein ending at the 42nd (or 43rd) residue. Proc Natl Acad Sci USA 1997; 94: 2025-30.
61. Xia W, Zhang J, Perez R, Koo EH, Selkoe DJ. Interaction between amyloid precursor protein and presenilins in mammalian cells: implications for the pathogenesis of Alzheimer disease. Proc Natl Acad Sci USA 1997; 94: 8208-13.
62. Ray WJ, Yao M, Nowotny P, Mumm J, Zhang W, Wu JY, et al. Evidence for a physical interaction between presenilin and Notch. Proc Natl Acad Sci USA 1999; 96: 3263-8.
63. Yu G, Nishimura M, Arawaka S, Levitan D, Zhang L, Tandon A, et al. Nicastrin modulates presenilin-mediated notch / glp-1 signal transduction and bAPP processing. Nature 2000; 407: 48-54.
64. Huppert SS, Le A, Schroeter EH, Mumm JS, Saxena MT, Milner LA, et al. Embryonic lethality in mice homozygous for a processing-deficient allele of Notch1. Nature 2000; 405: 966-70.
65. Steiner H, Haass C. Intramembrane proteolysisby presenilins. Nature Rev Mol Cell Biol 2000; 1: 217-24.
66. Petit A, Bihel F, Alves da Costa C, Pourquie O, Checler F, Kraus JL. New protease inhibitors prevent gamma-secretase-mediated production of Aβ 40/42 without affecting Notch cleavage. Nature Cell Biol 2001; 3: 507-11.
67. Dewachter I, Van Leuven F. Secretases as targets for the treatment of Alzheimer's disease: the prospects. Lancet Neurol 2002; 1: 409-16.
68. Avila J, Perez M, Lucas JJ, Gomez-Ramos A, Santa Maria I, Moreno F, et al. Assembly in vitro of tau protein and its implications in Alzheimer's disease. Curr Alzheimer Res 2004; 2: 97-101.
69. Terwel D, Dewachter I, Van Leuven F. Axonal transport, tau protein, and neurodegeneration in Alzheimer's disease. Neuromol Med 2002; 2: 151-65.
70. Delacourte A, David JP, Sergeant N, Buee L, Wattez A, Vermersch P, et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology 1999; 52: 1158-65.
71. Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Rev 2000; 1: 95-130.
72. Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow EM. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Cell Biol 2002; 156: 1051-63.
73. Gonzalez-Billault C, Engelke M, Jimenez-Mateos EM, Wandosell F, Caceres A, Avila J. Participation of structural microtubule-associated proteins (MAPs) in the development of neuronal polarity. J Neurosci Res 2002; 67: 713-9.
74. Augustinack JC, Schneider A, Mandelkow EM, Hyman BT. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol (Berl) 2002; 103: 26-35.
75. Alvarez A, Munoz JP, Maccioni RB. A Cdk5-p35 stable complex is involved in the beta-amyloid-induced deregulation of Cdk5 activity in hippocampal neurons. Exp Cell Res 2001; 264: 266-74.
76. Engel T, Lucas JJ, Gomez-Ramos P, Moran MA, Avila J, Hernandez F. Cooexpression of FTDP-17 tau and GSK-3beta in transgenic mice induce tau polymerization and neurodegeneration. Neurobiol Aging 2005. In press. (Epub ahead of print).
77. Mandelkow EM, Thies E, Trinczek B, Biernat J, Mandelkow E. MARK/PAR1 kinase is a regulator of microtubule-dependent transport in axons. J Cell Biol 2004; 167: 99-110.
78. Matenia D, Griesshaber B, Li XY, Thiessen A, Johne C, Jiao J, et al. PAK5 Kinase Is an Inhibitor of MARK/Par-1, Which Leads to Stable Microtubules and Dynamic Actin. Mol Biol Cell 2005; 16: 410-22.
79. Ruthel G, Hollenbeck PJ. Growth cones are not required for initial establishment of polarity or differential axon branch growth in cultured hippocampal neurons. J Neurosci 2000; 20: 2266-74.
80. Biernat J, Wu YZ, Timm T, Zheng-Fischhofer Q, Mandelkow E, Meijer L, et al. Protein kinase MARK/PAR-1 is required for neurite outgrowth and establishment of neuronal polarity. Mol Biol Cell 2002; 13: 4013-28.
81. Mandelkow EM, Stamer K, Vogel R, Thies E, Mandelkow E. Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol Aging 2003; 24: 1079-1085.
82. Ribe EM, Perez M, Puig B, Gich I, Lim F, Cuadrado M, et al. Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice. Neurobiol Dis 2005; 20: 814-22.
83. Zhu X, Smith MA, Perry G, Aliev G. Mitochondrial failures in Alzheimer's disease. Am J Alzheimers Dis Other Demen 2004; 19: 345-52.
84. Zhu X, Lee HG, Casadesus G, Avila J, Drew K, Perry G, Smith MA. Oxidative imbalance in Alzheimer's disease. Mol Neurobiol 2005; 31: 205-17.
85. Przedborski S, Ischiropoulos H. Reactive oxygen and nitrogen species: weapons of neuronal destruction in models of Parkinson's disease. Antioxid Redox Signal 2005; 7: 685-93.
86. Moreira PI, Smith MA, Zhu X, Santos MS, Oliveira CR, Perry G. Therapeutic potential of oxidant mechanisms in Alzheimer's disease. Expert Rev Neurother 2004; 4: 995-1004.
87. Michaelis ML. Drugs targeting Alzheimer's disease: some things old and some things new. J Pharmacol Exp Ther 2003; 304: 897-904.
88. Danysz W, Parsons CG. Neuroprotective potential of ionotropic glutamate receptor antagonists. Neurotox Res 2002; 4: 119-126.
89. Olney JW, Wozniak DF, Farber NB. Glumate receptor dysfunction and Alzheimer's disease. Restor Neurol Neurosci 1998; 13: 75-83.
90. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001; 60: 759-67.
91. Castellani RJ, Honda K, Zhu X, Cash AD, Nunomura A, Perry G, Smith MA. Contribution of redox-active iron and copper to oxidative damage in Alzheimer disease. Ageing Res Rev 2004; 3: 319-26.
92. Zhu X, Raina AK, Perry G, Smith MA. Alzheimer's disease: the two-hit hypothesis. Lancet Neurol 2004; 3: 219-26.
93. Aliev G, Smith MA, de la Torre JC, Perry G. Mitochondria as a primary target for vascular hypoperfusion and oxidative stress in Alzheimer's disease. Mitochondrion 2004; 4: 649-63.
94. Maccioni RB, Munoz JP, Barbeito L. The molecular bases of Alzheimer's disease and other neurodegenerative disorders. Arch Med Res 2001; 32: 367-81.
95. Shimohama S. Apoptosis in Alzheimer's disease. An update. Apoptosis 2000; 5: 9-16.
96. Jordan J, Galindo MF, Miller RJ. Role of calpain- and interleukin-1 beta converting enzyme-like proteases in the beta-amyloid-induced death of rat hippocampal neurons in culture. J Neurochem 1997; 68: 1612-21.
97. Hughes KA, Reynolds RM. Evolutionary and mechanistic theories of aging. Annu Rev Entomol 2005; 50: 421-5.
98. Droge W. Oxidative stress and aging. Adv Exp Med Biol 2003; 543: 191-200.
99. Houthoofd K, Braeckman BP, Johnson TE, Vanfleteren JR. Extending life-span in C. elegans. Science 2004; 305: 1238-9.
100. Ishii N, Senoo-Matsuda N, Miyake K, Yasuda K, Ishii T, Hartman PS, Furukawa S. Coenzyme Q10 can prolong C. elegans lifespan by lowering oxidative stress. Mech Ageing Dev 2004; 125: 41-6.
101. Nakashima H, Ishihara T, Yolota O, Terada S, Trojanowski JQ, Lee VM, et al. Effects of alpha-tocopherol on an animal model of tauopathies. Free Radic Biol Med 2004; 37: 176-86.
102. Feng Z, Zhang JT. Protective effect of melatonin on beta-amyloid-induced apoptosis in rat astroglioma C6 cells and its mechanism. Free Radic Biol Med 2004; 37: 1790-801.
103. Feng Z, Zhang JT. Melatonin reduces amyloid beta-induced apoptosis in pheochromocytoma (PC12) cells. J Pineal Res 2004; 37: 257-66.
104. Dhitavat S, Ortiz D, Shea TB, Rivera ER. Acetyl-L-carnitine protects against amyloid-beta neurotoxicity: roles of oxidative buffering and ATP levels. Neurochem Res 2002; 27: 501-55.
105. Behl C, Davis JB, Lesley R, Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 1994; 77: 817-27.
106. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005; 352: 2379-88.
107. Munoz FJ, Sole M, Coma M. The protective role of vitamin E in vascular amyloid beta-mediated damage. Subcell Biochem 2005; 38: 147-65.
108. Luchsinger JA, Mayeux R. Dietary factors and Alzheimer's disease. Lancet Neurol 2004; 3: 579-87.
109. Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, et al. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol 2004; 61: 82-8.
110. Battino M, Bompadre S, Leone L, Devecchi E, Degiuli A, D'Agostino F, et al. Coenzyme Q, vitamin E and Apo-E alleles in Alzheimer disease. Biofactors 2003; 18: 277-81.
111. Beal MF. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. J Bioenerg Biomembr 2004; 36: 381-6.
112. de Bustos F, Molina JA, Jimenez-Jimenez FJ, Garcia-Redondo A, Gomez-Escalonilla C, Porta-Etessam J, et al. Serum levels of coenzyme Q10 in patients with Alzheimer's disease. J Neural Transm 2000; 107: 233-9.
113. Lockshin RA, Zakari Z. Apoptosis, autophagy and more. Int J Biochem Cell Biol 2004; 36: 2405-19.
114. Kerr JFR. History of the events leading to the formulation of the apoptosis concept. Toxicology 2002; 181-182: 471-4.
115. Van Loo G, Saelens X, van Gurp M, MacFarlane M, Martin SJ, Vandenabeele P. The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet. Cell Death Diff 2002; 9: 1031-42.
116. Nicotera P, Leist M. Energy supply and the shape of death in neurons and lymphoid cells. Cell Death Differ 1997; 4: 435-42.
117. Reed JC. Apoptosis-regulating proteins as targets for drug discovery. Trends Mol Med 2001; 7: 314-9.
118. Troy CM, Salvesen GS. Caspases on the brain. J Neurosci Res 2002; 69: 145-50.
119. Friedlander RM. Apoptosis and caspases in neurodegenerative diseases. New England J Med 2003; 348: 1365-75.
120. D'Mello SR, Chin PC. Treating neurodegenerative conditions through the understanding of neuronal apoptosis. Curr Drug Targets CNS Neurol Disord 2005; 4: 3-23.
121. Stavrovskaya IG, Kristal BS. The powerhouse takes control of the cell: is the mitochondrial permeability transition a viable therapeutic target against neuronal dysfunction and death? Free Radic Biol Med 2005; 38: 687-97.
122. Rostovtseva TK, Tan W, Colombini M. On the role of VDAC in apoptosis: fact and fiction. J Bioenerg Biomembr 2005; 37: 129-42.
123. Rohn TT, Rissman RA, Davis MC, Kim YE, Cotman CW, Head E. Caspase-9 activation and caspase cleavage of tau in the Alzheimer's disease brain. Neurobiol Dis 2002; 11: 341-54.
124. Akgul C, Moulding DA, Edwards SW. Alternative splicing of Bcl-2-related genes: functional consequences and potential therapeutic applications. Cell Mol Life Sci 2004 61: 2189-99.
125. Takuma H, Tomiyama T, Kuida K, Mori H. Amyloid beta peptide-induced cerebral neuronal loss is mediated by caspase-3 in vivo. J Neuropathol Exp Neurol 2004; 63: 255-61.
126. Takuma K, Yan SS, Stern DM, Yamada K. Mitochondrial dysfunction, endoplasmic reticulum stress, and apoptosis in Alzheimer's disease. J Pharmacol Sci 2005; 97: 312-6.
127. Gastard MC, Troncoso JC, Koliatsos VE. Caspase activation in the limbic cortex of subjects with early Alzheimer's disease. Ann Neurol 2003; 54: 393-8.
128. LeBlanc A, Liu H, Goodyer C, Bergeron C, Hammond J. Caspase-6 role in apoptosis of human neurons, amyloidogenesis, and Alzheimer's disease. J Biol Chem 1999; 274: 23426-36.
129. Allen JW, Eldadah BA, Huang X, Knoblach SM, Faden AI. Multiple caspases are involved in beta-amyloid-induced neuronal apoptosis. J Neurosci Res 2001; 65: 45-53.
130. Harada J, Sugimoto M. Activation of caspase-3 in beta-amyloid-induced apoptosis of cultured rat cortical neurons. Brain Res 1999; 842: 311-23.
131. Rissman RA, Poon WW, Blurton-Jones M, Oddo S, Torp R, Vitek MP, et al. Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest 2004; 114: 121-30.
132. Cotman CW, Poon WW, Rissman RA, Blurton-Jones M. The role of caspase cleavage of tau in Alzheimer disease neuropathology. J Neuropathol Exp Neurol 2005; 64: 104-12.
133. Kang HJ, Yoon WJ, Moon GJ, Kim DY, Sohn S, Kwon HJ, Gwag BJ. Caspase-3-mediated cleavage of PHF-1 tau during apoptosis irrespective of excitotoxicity and oxidative stress: an implication to Alzheimer's disease. Neurobiol Dis 2005; 18: 450-8.
134. Guo H, Albrecht S, Bourdeau M, Petzke T, Bergeron C, LeBlanc AC. Active caspase-6 and caspase-6-cleaved tau in neuropil threads, neuritic plaques, and neurofibrillary tangles of Alzheimer's disease. Am J Pathol 2004; 165: 523-31.
135. Siman R, Card JP, Davis LG. Proteolytic processing of beta-amyloid precursor by calpain I. J Neurosci 1990; 10: 2400-11.
136. Rami A. Ischemic neuronal death in the rat hippocampus: the calpain-calpastatin-caspase hypothesis. Neurobiol Dis 2003; 13: 75-88.
137. Ray SK, Hogan EL, Banik NL. Calpain in the pathophysiology of spinal cord injury: neuroprotection with calpain inhibitors. Brain Res Rev 2003; 42: 169-85.
138. Kuwako K, Nishimura I, Uetsuki T, Saido TC, Yoshikawa K. Activation of calpain in cultured neurons overexpressing Alzheimer amyloid precursor protein. Mol Brain Res 2002; 107: 166-75.
139. Battaglia F, Trinchese F, Liu S, Walter S, Nixon RA, Arancio O. Calpain inhibitors, a treatment for Alzheimer's disease: position paper. J Mol Neurosci 2003; 20: 357-62.
140. Boland B, Campbell V. β-Amyloid (1-40)-induced apoptosis of cultured cortical neurones involves calpain-mediated cleavage of poly-Alzheimer's disease P-ribose polymerase. Neurobiol Aging 2003; 24: 179-86.
141. Sedarous M, Keramaris E, O'Hare M, Melloni E, Slack RS, Elce JS, et al. Calpains mediate p53 activation and neuronal death evoked by DNA damage. J Biol Chem 2003; 278: 26031-8.
142. Polster BM, Basanez G, Etxebarria A, Hardwick JM, Nicholls DG. Calpain I induces cleavage and release of apoptosis-inducing factor from isolated mitochondria. J Biol Chem 2005; 280: 6447-54.
143. Lau LF, Seymour PA, Sanner MA, Schachter JB. Cdk5 as a drug target for the treatment of Alzheimer's disease. J Mol Neurosci 2002; 19: 267-73.
144. Liu T, Perry G, Chan HW, Verdile G, Martins RN, Smith MA, et al. Amyloid-beta-induced toxicity of primary neurons is dependent upon differentiation-associated increases in tau and cyclin-dependent kinase 5 expression. J Neurochem 2004; 88: 554-63.
145. Otth C, Concha II, Arendt T, Stieler J, Schliebs R, Gonzalez-Billault C, et al. AbetaPP induces cdk5-dependent tau yperphosphorylation in transgenic mice Tg2576. J Alzheimers Dis 2002; 4: 417-30.
146. Cruz JC, Tseng HC, Goldman JA, Shih H, Tsai LH. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 2003; 40: 471-83.
147. Hallows JL, Chen K, DePinho RA, Vincent I. Decreased cyclin-dependent kinase 5 (cdk5) activity is accompanied by redistribution of cdk5 and cytoskeletal proteins and increased cytoskeletal protein phosphorylation in p35 null mice. J Neurosci 2003; 23: 10633-44.
148. Noble W, Olm V, Takata K, Casey E, Mary O, Meyerson J, et al. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 2003; 38: 555-65.
149. Van den Haute C, Spittaels K, Van Dorpe J, Lasrado R, Vandezande K, Laenen I, et al. Coexpression of human cdk5 and its activator p35 with human protein tau in neurons in brain of triple transgenic mice. Neurobiol Dis 2001; 8: 32-44.
150. Lee MS, Kwon YT, Li M, Peng J, Friedlander RM, Tsai LH. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 2000; 405: 360-4.
151. Cheung ZH, Ip NY. Cdk5: mediator of neuronal death and survival. Neurosci Lett 2004; 361: 47-51.
152. Tsai LH, Lee MS, Cruz J. Cdk5, a therapeutic target for Alzheimer's disease? Biochim Biophys Acta 2004; 1697: 137-42.
153. Lim AC, Qi RZ. Cyclin-dependent kinases in neural development and degeneration. J Alzheimers Dis 2003; 5: 329-35.
154. Mattson MP. NF-kappaB in the survival and plasticity of neurons. Neurochem Res 2005; 30: 883-93.
155. Culmsee C, Siewe J, Junker V, Retiounskaia M, Schwarz S, Camandola S, et al. Reciprocal inhibition of p53 and nuclear factor-kappaB transcriptional activities determines cell survival or death in neurons. J Neurosci 2003; 23: 8586-95.
156. Mattson MP, Camandola, S. NF-kappaB in neuronal plasticity and neurodegenerative disorders. J Clin Invest 2001; 107: 247-54.
157. Yao M, Nguyen TV, Pike CJ. Beta-amyloid-induced neuronal apoptosis involves c-Jun N-terminal kinase-dependent downregulation of Bcl-w. J Neurosci 2005; 25: 1149-58.
158. Ferrer I, Gomez-Isla T, Puig B, Freixes M, Ribe E, Dalfo E, Avila J. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies. Curr Alzheimer Res 2005; 2: 3-18.
159. Savage MJ, Lin YG, Ciallella JR, Flood DG, Scott RW. Activation of c-Jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition. J Neurosci 2002; 22: 3376-85.
160. Wang LH, Besirli CG, Johnson EM Jr. Mixed-lineage kinases: a target for the prevention of neurodegeneration. Annu Rev Pharmacol Toxicol 2004; 44: 451-74.
161. Chin PC, Majdzadeh N, D'Mello SR. Inhibition of GSK3beta is a common event in neuroprotection by different survival factors. Mol Brain Res 2005; 137: 193-201.
162. Bhat RV, Budd Haeberlein SL, Avila J. Glycogen synthase kinase 3: a drug target for CNS therapies. J Neurochem 2004; 89: 1313-7.
163. Cohen P, Goedert M. GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov 2004; 3: 479-87.
164. Mora A, Sabio G, Gonzalez-Polo RA, Cuenda A, Alessi DR, Alonso JC, et al. Lithium inhibits caspase 3 activation and dephosphorylation of PKB and GSK3 induced by K+ deprivation in cerebellar granule cells. J Neurochem 2001;78: 199-206.
165. Enguita M, DeGregorio-Rocasolano N, Abad A, Trullas R. Glycogen synthase kinase 3 activity mediates neuronal pentraxin 1 expression and cell death induced by potassium deprivation in cerebellar granule cells. Mol Pharmacol 2005; 67: 1237-46.
166. Alvarez G, Munoz-Montano JR, Satrustegui J, Avila J, Bogonez E, Diaz-Nido J. Regulation of tau phosphorylation and protection against beta-amyloid-induced neurodegeneration by lithium. Possible implications for Alzheimer's disease. Bipolar Disord 2002; 4: 153-65.
167. Alvarez G, Munoz-Montano JR, Satrustegui J, Avila J, Bogonez E, Diaz-Nido J. Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration. FEBS Lett 1999; 453: 260-4.
168. Facci L, Stevens DA, Skaper SD. Glycogen synthase kinase-3 inhibitors protect central neurons against excitotoxicity. Neuroreport 2003; 14: 1467-70.
169. Cross DA, Culbert AA, Chalmers KA, Facci L, Skaper SD, Reith AD. Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. J Neurochem 2001; 77: 94-102.
170. Hernandez F, Lim F, Lucas JJ, Perez-Martin C, Moreno F, Avila J. Transgenic mouse models with tau pathology to test therapeutic agents for Alzheimer's disease. Mini Rev Med Chem 2002; 2: 51-8.
171. Perez M, Hernandez F, Lim F, Diaz-Nido J, Avila J. Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J Alzheimers Dis 2003; 5: 301-8.
172. Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 2004; 29: 95-102.
173. Webber KM, Raina AK, Marlatt MW, Zhu X, Prat MI, Morelli L, et al. The cell cycle in Alzheimer disease: A unique target for neuropharmacology. Mech Ageing Dev 2005; 126: 1019-25.
174. Raina AK, Zhu X, Smith MA. Alzheimer's disease and the cell cycle. Acta Neurobiol Exp (Wars) 2004; 64: 107-12.
175. Bowser R, Smith MA. Cell cycle proteins in Alzheimer's disease: plenty of wheels but no cycle. J Alzheim Dis 2002; 4: 249-54.
176. Giovanni A, Wirtz-Brugger F, Keramaris E, Slack R, Park DS. Involvement of cell cycle elements, cyclin-dependent kinases, pRb, and E2F × DP, in B-amyloid-induced neuronal death. J Biol Chem 1999; 274: 19011-6.
177. Copani A, Sortino MA, Caricasole A, Chiechio S, Chisari M, Battaglia G, et al. Erratic expression of DNA polymerases by beta-amyloid causes neuronal death. FASEB J 2002; 16: 2006-8.
178. Copani A, Melchiorri D, Caricasole A, Martini F, Sale P, Carnevale R, et al. Beta-amyloid-induced synthesis of the ganglioside GD3 is a requisite for cell cycle reactivation and apoptosis in neurons. J Neurosci 2002; 22: 3963-8.
179. Copani A, Condorelli F, Canonico PL, Nicoletti F, Sortino MA. Cell cycle progression towards Alzheimer's disease. Funct Neurol 2001; 16: 11-5.
180. Copani A, Uberti D, Sortino MA, Bruno V, Nicoletti F, Memo M. Activation of cell-cycle-associated proteins in neuronal death: a mandatory or dispensable path? Trends Neurosci 2001; 24: 25-31.
181. Yang Y, Geldmacher DS, Herrup K. DNA replication precedes neuronal cell death in Alzheimer's disease. J Neurosci 2001; 21: 2661-8.
182. Yang Y, Mufson EJ, Herrup K. Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer's disease. J Neurosci 2003; 23: 2557-63.
183. Hou ST, Callaghan D, Fournier MC, Hill I, Kang L, Massie B, et al. The transcription factor E2F1 modulates apoptosis of neurons. J Neurochem
184. Hou ST, Cowan E, Walker T, Ohan N, Dove M, Rasqinha I, MacManus JP. The transcription factor E2F1 promotes dopamine-evoked neuronal apoptosis by a mechanism independent of transcriptional activation. J Neurochem 2001; 78: 287-97.
185. Arendt T. Dysregulation of neuronal differentiation and cell cycle control in Alzheimer's disease. J Neural Transm Suppl 2002; 62: 77-85.
186. Casadesus G, Atwood CS, Zhu X, Hartzler AW, Webber KM, Perry G, Bowen RL, Smith MA. Evidence for the role of gonadotropin hormones in the development of Alzheimer disease. Cell Mol Life Sci 2005; 62: 293-8.
187. Herrup K, Arendt T. Re-expression of cell cycle proteins induces neuronal cell death during Alzheimer's disease. J Alzheimers Dis 2002; 4: 243-7.
188. Herrup K, Neve R, Ackerman SL, Copani A. Divide and die: cell cycle events as triggers of nerve cell death. J Neurosci 2004; 24: 9232-9.
189. Busser J, Geldmacher DS, Herrup K. Ectopic cell cycle proteins predict the sites of neuronal cell death in Alzheimer's disease brain. J Neurosci 1998; 18: 2801-7.
190. Jordan-Sciutto KL, Malaiyandi LM, Bowser R. Altered distribution of cell cycle transcriptional regulators during Alzheimer disease. J Neuropathol Exp Neurol 2002; 61: 358-67.
191. Copani A, Sortino MA, Nicoletti F, Giuffrida SA. Alzheimer's disease research enters a "new cycle": how significant? Neurochem Res 2002; 27: 173-6.
192. Raina AK, Pardo P, Rottkamp CA, Zhu X, Pereira-Smith OM, Smith MA. Neurons in Alzheimer disease emerge from senescence. Mech Ageing Dev 2001; 123: 3-9.
193. Klein JA, Longo-Guess CM, Rossmann MP, Seburn KL, Hurd RE, Frankel WN, et al. The harlequin mouse mutation downregulates apoptosis-inducing factor. Nature 2002; 419: 367-74.
194. Biswas SC, Liu DX, Greene LA. Bim is a direct target of a neuronal E2F-dependent apoptotic pathway. J Neurosci 2005; 25: 8349-58.
195. Stevens C, La Thangue NB. The emerging role of E2F-1 in the DNA damage response and checkpoint control. DNA Repair 2004; 3: 1071-9.
196. Stevens C, La Thangue NB. E2F and cell cycle control: a double-edged sword. Arch Biochem Biophys 2003; 412: 157-69.
197. Culmsee C, Mattson MP. p53 in neuronal apoptosis. Biochem Biophys Res Commun 2005; 331: 761-77.
198. Duan W, Zhu X, Ladenheim B, Yu QS, Guo Z, Oyler J, et al. p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism. Ann Neurol 2002; 52: 597-606.
199. Culmsee C, Zhu X, Yu QS, Chan SL, Camandola S, Guo Z, et al. A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid beta-peptide. J Neurochem 2001; 77: 220-8.
200. Hershko T, Chaussepied M, Oren M, Ginsberg D. Novel link between E2F and p53: proapoptotic cofactors of p53 are transcriptionally upregulated by E2F. Cell Death Differ 2005; 12: 377-83.
201. Hershko T, Ginsberg D. Up-regulation of Bcl-2 homology 3 (BH3)-only proteins by E2F1 mediates apoptosis. J Biol Chem 2004; 279: 8627-34.
202. Verdaguer E, Jimenez A, Canudas AM, Jorda EG, Sureda FX, Pallas M, et al. Inhibition of cell cycle pathway by flavopiridol promotes survival of cerebellar granule cells after an excitotoxic treatment. J Pharmacol Exp Ther 2004; 308: 609-16.
203. Verdaguer E, Garcia-Jorda E, Canudas AM, Dominguez E, Jimenez A, Pubill D, et al. Kainic acid-induced apoptosis in cerebellar granule neurons: an attempt at cellcycle re-entry. Neuroreport 2002; 13: 413-6.
204. Verdaguer E, Jorda EG, Canudas AM, Jimenez A, Pubill D, Escubedo E, et al. Antiapoptotic effects of roscovitine in cerebellar granule cells deprived of serum and potassium: a cell cycle-related mechanism. Neurochem Int 2004; 44: 251-61.
205. Kruman II, Wersto RP, Cardozo-Pelaez F, Smilenov L, Chan SL, Chrest FJ, et al. Cell cycle activation linked to neuronal cell death initiated by DNA damage. Neuron 2004; 41: 549-61.
206. O'Hare MJ, Hou ST, Morris EJ, Cregan SP, Xu Q, Slack RS, Park DS. Induction and modulation of cerebellar granule neuron death by E2F-1. J Biol Chem 2000; 275: 25358-64.
207. Hoozemans JJ, O'Banion MK. The role of COX-1 and COX-2 in Alzheimer's disease pathology and the therapeutic potentials of non-steroidal anti-inflammatory drugs. Curr Drug Targets CNS Neurol Disord 2005; 4: 307-15.
208. Patrignani P, Tacconelli S, Sciulli MG, Capone ML. New insights into COX-2 biology and inhibition. Brain Res Rev 2005; 48: 352-9.
209. Minghetti L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 2004; 63: 901-10.
210. O'Banion MK. COX-2 and Alzheimer's disease: potential roles in inflammation and neurodegeneration. Expert Opin Investig Drugs 1999; 8: 1521-36.
211. Jang JH, Surh YJ. Beta-amyloid-induced apoptosis is associated with cyclooxygenase-2 up-regulation via the mitogen-activated protein kinase-NF-kappaB signaling pathway. Free Radic Biol Med 2005; 38: 1604-13.
212. Hoozemans JJ, Bruckner MK, Rozemuller AJ, Veerhuis R, Eikelenboom P, Arendt T. Cyclin D1 and cyclin E are co-localized with cyclo-oxygenase 2 (COX-2) in pyramidal neurons in Alzheimer disease temporal cortex. J Neuropathol Exp Neurol 2002; 61: 678-88.
213. Mayer ML. Glutamate receptor ion channels. Curr Opin Neurobiol 2005; 15: 282-8.
214. Palmer CL, Cotton L, Henley JM. The molecular pharmacology and cell biology of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. Pharmacol Rev 2005; 57: 253-77.
215. Wang CX, Shuaib A. NMDA/NR2B selective antagonists in the treatment of ischemic brain injury. Curr Drug Targets CNS Neurol Disord 2005; 4: 143-51.
216. Arundine M, Tymianski M. Molecular mechanisms of glutamate-dependent neurodegeneration in ischemia and traumatic brain injury. Cell Mol Life Sci 2004; 61: 657-68.
217. Danysz W, Parsons CG. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry 2003; 18 (Suppl 1): S23-32.
218. Arundine M, Tymianski M. Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity. Cell Calcium 2003; 4: 325-37.
219. Mandel S, Grunblatt E, Riederer P, Gerlach M, Levites Y, Youdim MB. Neuroprotective strategies in Parkinson's disease: an update on progress. CNS Drugs 2003; 17: 729-62.
220. Wilcock GK. Memantine for the treatment of dementia. Lancet Neurol 2003; 2: 503-5.
221. Molinuevo JL, Llado A, Rami L. Memantine: targeting glutamate excitotoxicity in Alzheimer's disease and other dementias. Am J Alzheimers Dis Other Demen 2005; 20: 77-85.
222. Plosker GL, Lyseng-Williamson KA. Memantine: a pharmaco-economic review of its use in moderate-to-severe Alzheimer's disease. Pharmacoeconomics 2005; 23: 193-206.
223. Beal MF. Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci 2000; 23: 298-304.
224. Schulz JB, Matthews RT, Henshaw DR, Beal MF. Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases. Neuroscience 1996; 71: 1043-8.
225. Lee HG, Perry G, Moreira PI, Garrett MR, Liu Q, Zhu X, et al. Tau phosphorylation in Alzheimer's disease: pathogen or protector? Trends Mol Med 2005; 11: 164-9.
226. Scarpini E, Scheltens P, Feldman H. Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol 2003; 2: 539-47.
227. Walsh DM, Selkoe DJ. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett 2004; 11: 213-28.
228. Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, et al. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 2003; 40: 1087-93.
229. Rogawski MA. What is the rationale for new treatment strategies in Alzheimer's disease? CNS Spectr 2004; 9(7 Suppl 5): 6-12.
230. Ghosh AK, Hong L, Tang J. Beta-secretase as a therapeutic target for inhibitor drugs. Curr Med Chem 2002; 9: 1135-44.
231. Farzan M, Schnitzler CE, Vasilieva N, Leung D, Choe H. BACE2, a beta -secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein. Proc Natl Acad Sci USA 2000; 97: 9712-7.
232. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ 2005; 331: 321-7.
233. Johannsen P. Long-term cholinesterase inhibitor treatment of Alzheimer's disease. CNS Drugs 2004; 18: 757-68.
234. Areosa SA, Sherriff F, McShane R. Memantine for dementia. Cochrane Database Syst Rev 2005; CD003154.
235. Berman K, Brodaty H. Tocopherol (vitamin E) in Alzheimer's disease and other neurodegenerative disorders. CNS Drugs 2004; 18: 807-25.
236. Vina J, Lloret A, Orti R, Alonso D. Molecular bases of the treatment of Alzheimer's disease with antioxidants: prevention of oxidative stress. Mol Aspects Med 2004; 25: 117-23.
237. Leon J, Acuña-Castroviejo D, Sainz RM, Mayo JC, Tan DX, Reiter RJ. Melatonin and mitochondrial function. Life Sci 2004; 75: 765-90.
238. Singer C, Tractenberg RE, Kaye J, Schafer K, Gamst A, Grundman M, et al. A multicenter, placebo- controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep 2003; 26: 893-901.
239. Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 2004; 18: 790-804.
240. Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease:systematic review and meta-analysis of observational studies. BMJ 2003; 327: 128-40.
241. Kuan CY, Burke RE. Targeting the JNK signaling pathway for stroke and Parkinson's diseases therapy. Curr Drug Targets CNS Neurol Disord 2005; 4: 63-7.
242. Leszek J, Inglot AD, Janusz M, Byczkiewicz F, Kiejna A, Georgiades J, et al. Colostrinin proline-rich polypeptide complex from ovine colostrums-a long-term study of its efficacy in Alzheimer's disease. Med Sci Monit 2002; 8: PI93-6.
243. Di Rosa G, Odrijin T, Nixon RA, Arancio O. Calpain inhibitors: a treatment for Alzheimer's disease J Mol Neurosci 2002; 19: 135-41.
244. Dunn N, Holmes C, Mullee M. Does lithium therapy protect against the onset of dementia? Alzheimer Dis Assoc Disord 2005; 19: 20-2.
245. Su Y, Ryder J, Li B, Wu X, Fox N, Solenberg P, et al. Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing. Biochemistry 2004; 43: 6899-908.
246. Osuga H, Osuga S, Wang F, Fetni R, Hogan MJ, Slack RS, et al. Cyclin-dependent kinases as a therapeutic target for stroke. Proc Natl Acad Sci USA 2000; 97: 10254-9.
247. Selkoe DJ. Folding proteins in fatal ways. Nature 2003; 18; 426: 900-4.
248. Anderson JJ, Holtz G, Baskin PP, Turner M, Rowe B, Wang B, et al. Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897. Biochem Pharmacol 2005; 69: 689-98.
249. Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS, et al. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet 2001; 10: 1317-24.
250. Churcher I, Beher D. Gamma-secretase as a therapeutic target for the treatment of Alzheimer's disease. Curr Pharm Des 2005; 11(26): 3363-82.
251. Huber A, Stuchbury G, Burkle A, Burnell J, Munch G. Neuroprotective therapies for Alzheimer's disease. Curr Pharm Des 2006; 12(6): 705-17.
252. Ringheim GE, Szczepanik AM. Brain inflammation, cholesterol, and glutamate as interconnected participants in the pathology of Alzheimer's disease. Curr Pharm Des 2006; 12(6): 719-38.